Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BRCA1 deficiencies cause breast and ovarian cancer, rendering tumours hypersensitive to PARP inhibitors. Patient treatment can become ineffective due to emerging resistance mechanisms. Ross Chapman’s team at the Welcome Centre has uncovered a protein complex termed Shieldin that acts with 53BP1 to limit end resection at DNA double-strand breaks, which confers resistance to cancer treatment.

Sarah Bonham, Roman Fischer and Benedikt Kessler from the TDI were part of this study published in Nature.